Stay updated with breaking news from Takeda Development Center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New biomarker tests identified NASH and related conditions at least as well as common lab tests, paving the way for blood-based alternatives to liver biopsy for clinical care and therapeutic trials.
For patients with narcolepsy type 1, an orexin receptor 2 agonist, TAK-994, improves measures of sleepiness and cataplexy.
For patients with narcolepsy type 1, TAK-994 improves measures of sleepiness and cataplexy over 8 weeks compared with placebo.
Improvement seen in measures of sleepiness, cataplexy over eight weeks versus placebo, but drug was associated with hepatotoxic effects.
Press release content from Business Wire. The AP news staff was not involved in its creation.